Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$8.94 -3.8%	$7.54	$5.00 ▼ $20.80	$523.22M	1.25	1.46 million shs	952,131 shs
ERAS Erasca	$1.48 -3.3%	$1.33	$1.01 ▼ $3.45	$419.27M	1.09	1.75 million shs	1.46 million shs
IVVD Invivyd	$0.79 -6.5%	$0.71	$0.35 ▼ $2.74	$95.01M	0.63	4.52 million shs	780,998 shs
RAPP Rapport Therapeutics	$11.19 +0.4%	$10.51	$6.43 ▼ $29.74	$408.41M	N/A	170,902 shs	101,121 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	-5.06%	+27.70%	+14.02%	+32.52%	-56.15%
ERAS Erasca	+0.66%	-2.55%	+15.04%	+6.25%	-31.08%
IVVD Invivyd	-2.55%	-8.46%	-1.64%	+5.23%	-48.68%
RAPP Rapport Therapeutics	-7.93%	-9.65%	+11.51%	+5.99%	+1,113,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNA Ginkgo Bioworks	0.5984 of 5 stars	0.8	1.0	1.6	2.5	1.3
ERAS Erasca	2.7625 of 5 stars	3.5	0.0	3.8	2.5	1.3
IVVD Invivyd	3.7889 of 5 stars	3.6	4.0	2.7	3.3	1.3
RAPP Rapport Therapeutics	1.9591 of 5 stars	3.5	0.0	3.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	1.67	Reduce	$5.77	-35.49% Downside
ERAS Erasca	3.00	Buy	$4.57	208.88% Upside
IVVD Invivyd	3.25	Buy	$5.85	638.64% Upside
RAPP Rapport Therapeutics	3.00	Buy	$32.67	191.93% Upside

Current Analyst Ratings Breakdown

Latest IVVD, RAPP, ERAS, and DNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$28.00
4/8/2025	RAPP Rapport Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform
3/26/2025	ERAS Erasca	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/21/2025	ERAS Erasca	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/21/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/20/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$237.42M	2.20	N/A	N/A	$21.93 per share	0.41
ERAS Erasca	N/A	N/A	N/A	N/A	$2.10 per share	N/A
IVVD Invivyd	$36.69M	2.59	N/A	N/A	$1.61 per share	0.49
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$892.87M	-$9.16	N/A	N/A	N/A	-298.78%	-58.54%	-34.24%	8/14/2025 (Estimated)
ERAS Erasca	-$125.04M	-$0.62	N/A	N/A	N/A	N/A	-42.26%	-34.97%	8/11/2025 (Estimated)
IVVD Invivyd	-$198.64M	-$1.20	N/A	7.20	N/A	N/A	-155.33%	-114.88%	8/13/2025 (Estimated)
RAPP Rapport Therapeutics	-$34.79M	-$3.45	N/A	N/A	N/A	N/A	N/A	N/A	8/14/2025 (Estimated)

Latest IVVD, RAPP, ERAS, and DNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/20/2025	Q4 2024	IVVD Invivyd	-$0.25	-$0.15	+$0.10	-$0.15	$13.57 million	$13.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	5.79	5.79
ERAS Erasca	N/A	11.00	11.00
IVVD Invivyd	N/A	1.92	1.58
RAPP Rapport Therapeutics	N/A	45.91	45.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
ERAS Erasca	67.78%
IVVD Invivyd	70.36%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	9.72%
ERAS Erasca	14.40%
IVVD Invivyd	25.40%
RAPP Rapport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	58.53 million	51.89 million	Optionable
ERAS Erasca	120	283.29 million	221.94 million	Optionable
IVVD Invivyd	100	119.96 million	98.21 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A

IVVD, RAPP, ERAS, and DNA Headlines

Recent News About These Companies

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)

June 12 at 1:57 PM | marketbeat.com

Stifel reiterates buy rating for Rapport Therapeutics stock

June 5, 2025 | uk.investing.com

Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline

June 4, 2025 | nasdaq.com

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 16% - Still a Buy?

June 4, 2025 | marketbeat.com

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

June 2, 2025 | globenewswire.com

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025 | globenewswire.com

Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Monday

May 27, 2025 | marketbeat.com

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 21, 2025 | globenewswire.com

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth

May 17, 2025 | finance.yahoo.com

Crestline Management LP Acquires New Stake in Rapport Therapeutics (NASDAQ:RAPP)

May 13, 2025 | marketbeat.com

Rapport Therapeutics Reports Q1 2025 Financial Results

May 10, 2025 | tipranks.com

Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments

May 8, 2025 | tipranks.com

Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.

May 8, 2025 | tipranks.com

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

May 8, 2025 | globenewswire.com

Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform

May 7, 2025 | finance.yahoo.com

Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%

May 3, 2025 | aaii.com

Mise à disposition du rapport financier annuel 2024

April 30, 2025 | globenewswire.com

Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 7.06%

April 29, 2025 | aaii.com

Rapport Therapeutics to Participate in Upcoming Investor Conferences

April 22, 2025 | globenewswire.com

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

April 18, 2025 | nytimes.com

Rapport Therapeutics initiated with an Outperform at Citizens JMP

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, RAPP, ERAS, and DNA Company Descriptions

Ginkgo Bioworks NYSE:DNA

$8.94 -0.35 (-3.78%)

Closing price 03:59 PM Eastern

Extended Trading

$8.99 +0.05 (+0.58%)

As of 04:39 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Erasca NASDAQ:ERAS

$1.48 -0.05 (-3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.49 +0.01 (+0.68%)

As of 04:03 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Invivyd NASDAQ:IVVD

$0.79 -0.05 (-6.47%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-0.88%)

As of 04:38 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Rapport Therapeutics NASDAQ:RAPP

$11.19 +0.05 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$12.34 +1.16 (+10.32%)

As of 04:30 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time